Uribe M, Rojas S, Casián C, Sierra J G, Moreno J, Lewis H, Guevara L
Rev Gastroenterol Mex. 1980 Apr-Jun;45(2):63-8.
The combination of furosemide-amiloride was used in the management of fluid retention in 16 cirrhotic patients. The study lasted 60 days. In 15 out of the 16 patients a clinical response was observed, namely increased urinary volumen and reduction of abdominal girth. The body weight was reduced by a mean of 7.7 Kg. Serum potassium rose, within normal limits, in 14 patients and a reduction of urinary potassium elimination was observed. Mild hepatic encephalopathy was noticeable in 3 cases, rapidly responding to treatment reduction or withdrawal. The combination of furosemide-amiloride seems to be of value in the management of fluid retention in liver cirrhosis and is uncommonly associated to side effects.
速尿-氨氯吡咪联合用药用于16例肝硬化患者的液体潴留治疗。研究持续60天。16例患者中有15例观察到临床反应，即尿量增加和腹围减小。体重平均减轻7.7千克。14例患者血清钾升高且在正常范围内，同时观察到尿钾排泄减少。3例出现轻度肝性脑病，减少或停用治疗后迅速缓解。速尿-氨氯吡咪联合用药在肝硬化液体潴留治疗中似乎有价值，且副作用罕见。
